Compare Stocks: NBTX, RYTM, SRRK, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRM Mirum Pharmaceuticals	$100.61 +2.3%	$107.36	$63.23 ▼ $130.00	$6.38B	0.49	466,135 shs	586,934 shs
NBTX Nanobiotix	$37.60 +2.6%	$39.71	$9.32 ▼ $57.14	$1.85B	0.81	165,713 shs	200,137 shs
RYTM Rhythm Pharmaceuticals	$102.20 +1.1%	$108.84	$74.50 ▼ $122.20	$6.93B	1.97	443,722 shs	422,883 shs
SRRK Scholar Rock	$55.67 +1.9%	$53.55	$27.07 ▼ $61.76	$6.65B	0.67	1.07 million shs	1.18 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRM Mirum Pharmaceuticals	+2.35%	-0.02%	+2.42%	+1.27%	+34.34%
NBTX Nanobiotix	+2.62%	-6.00%	-2.89%	+5.80%	+293.18%
RYTM Rhythm Pharmaceuticals	+1.13%	-2.56%	-9.44%	+15.64%	+1.92%
SRRK Scholar Rock	+1.92%	-0.48%	+6.91%	+26.01%	+78.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRM Mirum Pharmaceuticals	$100.61 +2.3%	$107.36	$63.23 ▼ $130.00	$6.38B	0.49	466,135 shs	586,934 shs
NBTX Nanobiotix	$37.60 +2.6%	$39.71	$9.32 ▼ $57.14	$1.85B	0.81	165,713 shs	200,137 shs
RYTM Rhythm Pharmaceuticals	$102.20 +1.1%	$108.84	$74.50 ▼ $122.20	$6.93B	1.97	443,722 shs	422,883 shs
SRRK Scholar Rock	$55.67 +1.9%	$53.55	$27.07 ▼ $61.76	$6.65B	0.67	1.07 million shs	1.18 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRM Mirum Pharmaceuticals	+2.35%	-0.02%	+2.42%	+1.27%	+34.34%
NBTX Nanobiotix	+2.62%	-6.00%	-2.89%	+5.80%	+293.18%
RYTM Rhythm Pharmaceuticals	+1.13%	-2.56%	-9.44%	+15.64%	+1.92%
SRRK Scholar Rock	+1.92%	-0.48%	+6.91%	+26.01%	+78.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.31	36.48% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$37.33	-0.71% Downside
RYTM Rhythm Pharmaceuticals	2.74	Moderate Buy	$141.12	38.08% Upside
SRRK Scholar Rock	3.06	Buy	$58.77	5.57% Upside

Current Analyst Ratings Breakdown

Latest NBTX, RYTM, SRRK, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/8/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/8/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/27/2026	MIRM Mirum Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/27/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/27/2026	MIRM Mirum Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$137.00
8/21/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$64.00
8/13/2026	SRRK Scholar Rock	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $63.00
8/10/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/10/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MIRM Mirum Pharmaceuticals	$521.31M	12.53	$0.05 per share	1,928.24	$6.12 per share	16.44
NBTX Nanobiotix	$36.87M	51.62	N/A	N/A	($1.97) per share	-19.09
RYTM Rhythm Pharmaceuticals	$189.76M	36.91	N/A	N/A	$2.08 per share	49.13
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
NBTX Nanobiotix	-$27.11M	N/A	N/A	376.00	N/A	N/A	N/A	N/A	9/29/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	11/13/2026 (Estimated)

Latest NBTX, RYTM, SRRK, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/29/2026	H1 2026	NBTX Nanobiotix	-$0.1479	N/A	N/A	N/A	$27.25 million	N/A
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
NBTX Nanobiotix	N/A	1.09	1.09
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
SRRK Scholar Rock	0.77	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MIRM Mirum Pharmaceuticals	N/A
NBTX Nanobiotix	38.81%
RYTM Rhythm Pharmaceuticals	N/A
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
MIRM Mirum Pharmaceuticals	8.32%
NBTX Nanobiotix	3.45%
RYTM Rhythm Pharmaceuticals	5.90%
SRRK Scholar Rock	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
NBTX Nanobiotix	100	50.62 million	48.87 million	Not Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable
SRRK Scholar Rock	289	121.79 million	109.24 million	Optionable

NBTX, RYTM, SRRK, and MIRM Headlines

Recent News About These Companies

Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10 at 8:01 PM | seekingalpha.com

Scholar Rock Holding Corporation $SRRK Stock Position Lifted by Squarepoint Ops LLC

September 10 at 5:21 AM | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Scholar Rock (NASDAQ:SRRK)

September 10 at 1:24 AM | americanbankingnews.com

Scholar Rock's (SRRK) Buy Rating Reaffirmed at HC Wainwright

September 8 at 8:11 AM | marketbeat.com

Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise

September 7, 2026 | seekingalpha.com

Legal & General Group Plc Invests $3.36 Million in Scholar Rock Holding Corporation $SRRK

September 5, 2026 | marketbeat.com

Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug

September 2, 2026 | finance.yahoo.com

Senator Investment Group LP Acquires New Stake in Scholar Rock Holding Corporation $SRRK

August 31, 2026 | marketbeat.com

122,223 Shares in Scholar Rock Holding Corporation $SRRK Acquired by The Manufacturers Life Insurance Company

August 31, 2026 | marketbeat.com

Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK

August 31, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires New Shares in Scholar Rock Holding Corporation $SRRK

August 31, 2026 | marketbeat.com

104,346 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Man Group plc

August 30, 2026 | marketbeat.com

Algert Global LLC Grows Stock Holdings in Scholar Rock Holding Corporation $SRRK

August 29, 2026 | marketbeat.com

Jupiter Topco LLC Invests $123.28 Million in Scholar Rock Holding Corporation $SRRK

August 27, 2026 | marketbeat.com

96,285 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Artia Global Partners LP

August 27, 2026 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Shares Up 5.8% - Still a Buy?

August 26, 2026 | marketbeat.com

EFG International AG Takes Position in Scholar Rock Holding Corporation $SRRK

August 26, 2026 | marketbeat.com

Nicholas Investment Partners LP Purchases New Position in Scholar Rock Holding Corporation $SRRK

August 25, 2026 | marketbeat.com

9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.

August 25, 2026 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Sets New 52-Week High - Should You Buy?

August 24, 2026 | marketbeat.com

303,268 Shares in Scholar Rock Holding Corporation $SRRK Bought by Deutsche Bank AG

August 23, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX, RYTM, SRRK, and MIRM Company Descriptions

Mirum Pharmaceuticals NASDAQ:MIRM

$100.61 +2.31 (+2.35%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$101.83 +1.22 (+1.22%)

As of 07:06 AM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Nanobiotix NASDAQ:NBTX

$37.60 +0.96 (+2.62%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$36.99 -0.61 (-1.63%)

As of 05:07 AM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Rhythm Pharmaceuticals NASDAQ:RYTM

$102.20 +1.14 (+1.13%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$102.90 +0.70 (+0.68%)

As of 07:00 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Scholar Rock NASDAQ:SRRK

$55.67 +1.05 (+1.92%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$56.04 +0.36 (+0.66%)

As of 07:09 AM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBTX, RYTM, SRRK, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBTX, RYTM, SRRK, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBTX, RYTM, SRRK, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX, RYTM, SRRK, and MIRM Company Descriptions

Mirum Pharmaceuticals NASDAQ:MIRM

Nanobiotix NASDAQ:NBTX

Rhythm Pharmaceuticals NASDAQ:RYTM

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBTX, RYTM, SRRK, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBTX, RYTM, SRRK, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBTX, RYTM, SRRK, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX, RYTM, SRRK, and MIRM Company Descriptions

Mirum Pharmaceuticals NASDAQ:MIRM

Nanobiotix NASDAQ:NBTX

Rhythm Pharmaceuticals NASDAQ:RYTM

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools